Jianda Hu Selected Research

Immunoglobulin G (IgG)

1/2022	Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow-up of the multicenter, single-arm, Phase 2 study.
10/2020	Changes of hematological and immunological parameters in COVID-19 patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jianda Hu Research Topics

Disease

21	Neoplasms (Cancer) 04/2024 - 06/2013
16	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2024 - 11/2014
11	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2024 - 10/2017
10	Leukemia 01/2024 - 08/2011
10	Multiple Myeloma 01/2024 - 01/2017
10	Hematologic Neoplasms (Hematological Malignancy) 01/2024 - 11/2014
9	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 02/2024 - 06/2013
9	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2023 - 06/2013
8	Neutropenia 01/2022 - 10/2012
6	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2023 - 01/2018
6	Mycoses (Diseases, Fungus) 08/2021 - 02/2012
5	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 09/2023 - 01/2020
5	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 07/2023 - 01/2021
5	Invasive Fungal Infections 07/2021 - 02/2012
4	Lymphoma (Lymphomas) 01/2024 - 01/2020
4	Infections 07/2023 - 11/2017
3	Graft vs Host Disease (Graft-Versus-Host Disease) 11/2023 - 01/2020
3	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 01/2019
3	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022 - 01/2021
3	Hemorrhage 01/2022 - 01/2020
3	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022 - 02/2015
3	Sepsis (Septicemia) 01/2021 - 05/2019
3	Burkitt Lymphoma (Burkitt's Lymphoma) 12/2019 - 10/2002
2	Febrile Neutropenia 01/2024 - 10/2019
2	Hyperuricemia 01/2024 - 09/2020
2	Carcinogenesis 01/2024 - 01/2018
2	Disease Progression 01/2023 - 01/2018
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2023 - 12/2019
2	Primary Myelofibrosis (Myelosclerosis) 12/2022 - 11/2021
2	Hemophilia A (Haemophilia) 01/2022 - 12/2016
2	Urinary Tract Infections (Urinary Tract Infection) 01/2022 - 01/2021
2	Thrombocytopenia (Thrombopenia) 01/2022 - 01/2022
2	Hematologic Diseases (Blood Diseases) 08/2021 - 06/2019
2	Hypertension (High Blood Pressure) 03/2021 - 01/2020
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2021 - 10/2017
2	Diarrhea 01/2020 - 01/2018
2	T-Cell Lymphoma (Lymphoma, T Cell) 10/2017 - 01/2015
1	Pneumonia (Pneumonitis) 01/2024
1	Renal Insufficiency (Renal Failure) 01/2024
1	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 01/2024

Drug/Important Bio-Agent (IBA)

8	zanubrutinibIBA 09/2023 - 01/2020
7	Imatinib Mesylate (Gleevec)FDA Link 02/2024 - 02/2015
7	Rituximab (Mabthera)FDA Link 01/2024 - 01/2015
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2011
5	Bortezomib (Velcade)FDA Link 01/2024 - 01/2018
5	Emodin (Archin)IBA 11/2023 - 11/2014
5	Dexamethasone (Maxidex)FDA LinkGeneric 10/2023 - 01/2021
5	Inosine Triphosphate (ITP)IBA 07/2023 - 01/2021
5	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2021 - 08/2011
4	Chimeric Antigen ReceptorsIBA 01/2023 - 07/2022
4	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 01/2020
4	NucleophosminIBA 01/2021 - 08/2011
4	Messenger RNA (mRNA)IBA 12/2019 - 10/2002
3	nilotinib FDA Link 02/2024 - 04/2015
3	Dasatinib (BMS 354825)FDA Link 02/2024 - 09/2015
3	Proteasome InhibitorsIBA 01/2024 - 01/2017
3	orelabrutinibIBA 11/2023 - 01/2023
3	Interleukin-6 (Interleukin 6)IBA 10/2020 - 12/2002
3	Tyrosine Kinase InhibitorsIBA 06/2019 - 04/2015
3	Cytarabine (Cytosar-U)FDA LinkGeneric 02/2019 - 01/2016
3	baicalinIBA 01/2018 - 05/2012
2	Fatty Acids (Saturated Fatty Acids)IBA 04/2024 - 01/2017
2	Biosimilar PharmaceuticalsIBA 01/2024 - 01/2020
2	BilirubinIBA 01/2024 - 01/2024
2	Etoposide (VP 16)FDA LinkGeneric 01/2024 - 05/2023
2	NucleolinIBA 12/2023 - 12/2019
2	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2023 - 08/2021
2	daratumumabIBA 01/2023 - 01/2021
2	axicabtagene ciloleucelIBA 01/2023 - 07/2022
2	Immunoglobulin G (IgG)IBA 01/2022 - 10/2020
2	Factor VIII (Coagulation Factor VIII)IBA 01/2022 - 12/2016
2	camrelizumabIBA 01/2022 - 12/2019
2	hetrombopagIBA 01/2022 - 01/2021
2	AntibodiesIBA 01/2022 - 10/2020
2	posaconazole FDA Link 07/2021 - 02/2012
2	carfilzomibIBA 03/2021 - 01/2017
2	ibrutinibIBA 02/2021 - 01/2018
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 11/2017
2	Hemoglobins (Hemoglobin)IBA 10/2020 - 09/2020
2	ProcalcitoninIBA 10/2020 - 10/2019
2	MicroRNAs (MicroRNA)IBA 01/2020 - 01/2017
2	Drug CombinationsIBA 01/2019 - 01/2017
2	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 01/2018
2	baicaleinIBA 01/2018 - 11/2014
2	Micafungin (FK463)FDA Link 01/2018 - 10/2012
2	DNA (Deoxyribonucleic Acid)IBA 10/2017 - 01/2015
1	flumatinibIBA 02/2024
1	Amylases FDA Link 01/2024
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2024
1	Syk KinaseIBA 01/2024
1	XenobioticsIBA 01/2024
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2024

Therapy/Procedure

27	Therapeutics 04/2024 - 02/2012
17	Drug Therapy (Chemotherapy) 01/2024 - 02/2015
8	Hematopoietic Stem Cell Transplantation 01/2024 - 01/2015
3	Immunotherapy 01/2023 - 07/2022
3	Transplantation 08/2021 - 01/2015
2	Salvage Therapy 07/2021 - 02/2012
2	Central Venous Catheters 06/2019 - 08/2017
2	Induction Chemotherapy 06/2019 - 02/2015